Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Gains from Investment Securities (2016 - 2025)

Adma Biologics (ADMA) has disclosed Gains from Investment Securities for 10 consecutive years, with $1.7 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Gains from Investment Securities changed N/A year-over-year to $1.7 million, compared with a TTM value of $1.7 million through Mar 2025, up 23592.26%, and an annual FY2023 reading of $17000.0, down 52.78% over the prior year.
  • Gains from Investment Securities was $1.7 million for Q1 2025 at Adma Biologics, up from $1000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.7 million in Q1 2025 and bottomed at $1000.0 in Q4 2023.
  • Average Gains from Investment Securities over 4 years is $288149.8, with a median of $8941.0 recorded in 2022.
  • The sharpest move saw Gains from Investment Securities skyrocketed 100.51% in 2021, then crashed 99.38% in 2022.
  • Year by year, Gains from Investment Securities stood at $8493.0 in 2021, then grew by 2.66% to $8719.0 in 2022, then tumbled by 88.53% to $1000.0 in 2023, then skyrocketed by 165745.8% to $1.7 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ADMA at $1.7 million in Q1 2025, $1000.0 in Q4 2023, and $6000.0 in Q2 2023.